UNSPSC 51123706: Bunaftine

This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) GH09PRQ3FU, chemically known as 1-naphthalenecarboxamide, n-butyl-n-(2-(diethylamino)ethyl)- but more generally known as bunaftine, which bears US NIH Compound Identifier 36131. European Medicines Agency schedules Bunaftine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05973MIG.

UNSPSC 51123706 Bunaftine is a Commodity code covering advanced life support and emergency medications procured by state and local health agencies, fire rescue departments, and pharmacy benefit programs. State and local governments buy these medications for emergency medical services, hospital formularies, and state health plan beneficiaries — typically in specific unit quantities with strict expiration-date and shelf-life requirements, warranty periods, and compliance with FDA, OSHA, and drug-supply-chain regulations. Issuing bodies include municipal fire rescue services, state health and human services commissions, and cooperative purchasing alliances representing multiple state and local government facilities. The scope encompasses sealed-bid procurement for individual medication line items (such as Labetalol, Epinephrine, Adenosine, and Diltiazem), requests for information to establish direct-to-manufacturer pharmacy programs, and cooperative RFPs for multi-source generic pharmaceuticals distributed through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department solicited sealed bids (No. 26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000.00 and a one-year term plus optional renewals, designating a 5 percent SLBE bid discount. Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs serving state employee and retiree health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (No. S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with awards effective July 1, 2026. All recent solicitations require compliance with cGMP, DSCSA, FDA regulations, and comprehensive insurance and Safety Data Sheets documentation.